v3.26.1
Segment Reporting (Tables)
9 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of segment reporting information
          
   Nine months ended   Nine months ended 
   March 31, 2026   March 31, 2025 
         
Clinical studies  $6,602,000   $4,097,000 
Clinical teams   3,255,000    2,968,000 
Chemistry, manufacturing and controls   142,000    726,000 
Other research and development expenses   384,000    251,000 
General and administrative expenses   6,377,000    6,189,000 
Amortization of intangible assets   172,000    172,000 
Other income, net   (505,000)   (350,000)
Net loss  $(16,427,000)  $(14,053,000)